Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women.
The release of contraceptive steroids through different drug delivery systems into serum and breast milk was investigated in a group of lactating women. Four women in each group were taking either a low dosage progestogen compound like norethisterone (NET) 350 micrograms or d-norgestrel (d-Ng) 50 micrograms alone or low dosage combination pills containing NET 1 mg or d-Ng 150 micrograms with 30 micrograms ethinyl estradiol (EE2) or a biodegradable implant containing 25 mg NET or d-Ng. Peak levels in plasma and milk were seen in oral contraceptive users around 2 hours. Of the two low dosage progestogen compounds, d-Ng was below the detection limit in milk within 4 hours whereas NET was still detectable at the 24-hour interval. In contrast to this, because of the larger quantity of steroids in the combination pills, the NET/d-Ng levels in serum as well as in milk were high throughout the 24-hour period. With the subdermal route because of the sustained low release of the drug from the biodegradable implants, the levels in milk were below the detection limit within a day with d-Ng and within a week with NET.
D004343:Drug Implants; D004997:Ethinyl Estradiol / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D008895:Milk, Human / Q000032:analysis*; D009640:Norethindrone / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D009644:Norgestrel / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*
D004343:Drug Implants; D009644:Norgestrel; D004997:Ethinyl Estradiol; D009640:Norethindrone